As previously shown, IDH—mutant gliomas comprise approximately 70–80% of histologically low-grade gliomas, commonly occuring in patients under the age of 50, and generally responding better to treatment than IDH—wildtype gliomas [38,39,40,41,42]. The gene discussed is IDH2; the disease is central nervous system cancer.